𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

✍ Scribed by Michael Wang; Luis Fayad; Nicolaus Wagner-Bartak; Liang Zhang; Fredrick Hagemeister; Sattva S Neelapu; Felipe Samaniego; Peter McLaughlin; Michelle Fanale; Anas Younes; Fernando Cabanillas; Nathan Fowler; Kate J Newberry; Luhong Sun; Ken H Young; Richard Champlin; Larry Kwak; Lei Feng; Maria Badillo; Maria Bejarano; Kimberly Hartig; Wendy Chen; Yiming Chen; Catriona Byrne; Neda Bell; Jerome Zeldis; Jorge Romaguera

Book ID
117786109
Publisher
The Lancet
Year
2012
Tongue
English
Weight
141 KB
Volume
13
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 trial of rituximab plus hyper-CV
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV

Pixantrone dimaleate in combination with
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort
✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 166 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone